CELLECTISAct. Nom. News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

13.11.18	Cellectis Reports Financial Results for 3rd Quarter and First Nine Months 2018 (Businesswire)
19.09.18	CAR-T Pioneer Dr. Stephan A. Grupp to Join Cellectis Clinical Advisory Board (Businesswire)
18.09.18	Calyxt Appoints CEO, Jim Blome, Former President & CEO of Bayer CropScience LP (Businesswire)
02.08.18	Cellectis Appoints Stefan Scherer M.D., Ph.D., as Senior Vice President Clinical Development and Deputy Chief Medical Officer (Businesswire)
01.08.18	Cellectis Reports Financial Results for 2nd Quarter and First Six Months 2018 (Businesswire)
27.06.18	Cellectis S.A. Reports Results from Annual General Meeting Held on June 26, 2018 (Businesswire)
12.06.18	Cellectis Publishes Novel Methods to Improve the Clinical Use of Chimeric Antigen Receptor T-Cell Therapy in Scientific Reports (Businesswire)
04.06.18	FDA Grants Cellectis IND Approval for UCART22 in B-ALL (Businesswire)
23.05.18	INSERTING and REPLACING: Approval of UCART123 Amendment in AML to Accelerate Clinical Development (Businesswire)
22.05.18	Cellectis: Approval of UCART123 Amendment in AML to Accelerate Clinical Development (Businesswire)
21.05.18	Cellectis S.A.: Calyxt Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares (Businesswire)
15.05.18	Calyxt Announces Launch of Proposed Follow-On Offering (Businesswire)
10.05.18	Cellectis to Present Data at the 2018 ASGCT Annual Meeting (Businesswire)
07.05.18	Cellectis Reports 1st Quarter 2018 Financial Results (Businesswire)
02.05.18	Cellectis Files IND for UCART22 in Acute Lymphoblastic Leukemia (B-ALL) (Businesswire)
01.05.18	Harvard’s Wyss Institute Partners with Cellectis to Recode the Human Genome (Businesswire)
11.04.18	Cellectis to Present Data at the 2018 AACR Annual Meeting (Businesswire)
10.04.18	Cellectis Announces Closing of Follow-On Offering (Businesswire)
05.04.18	Cellectis Announces Pricing of Follow-On Offering (Businesswire)
03.04.18	Cellectis Announces Launch of Follow-On Offering (Businesswire)
03.04.18	Cellectis and Allogene Therapeutics Intend to Continue Strategic Cancer Immunotherapy Collaboration to Accelerate Development and Commercialization of Allogeneic Off-the-Shelf CAR T Therapies (Businesswire)
13.03.18	Dr. Mathieu Simon to Retire as Cellectis’ Chief Operating Officer; Elsy Boglioli Named as Successor (Businesswire)
12.03.18	Cellectis Reports 4th Quarter and Full Year 2017 Financial Results (Businesswire)
08.03.18	Cellectis: Servier and Pfizer Announce Results of UCART19 First-in-Human Trials to Be Presented at the 44th EBMT (European Society for Blood and Marrow Transplantation) Annual Meeting (Businesswire)
13.02.18	Two Issued U.S. Patents Granted to Cellectis for CRISPR Use in T-Cells (Businesswire)
06.02.18	Cellectis: Monthly Information on Share Capital and Company Voting Rights (Businesswire)
08.01.18	Cellectis: Monthly Information on Share Capital and Company Voting Rights (Businesswire)
02.01.18	Cellectis to Present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 12:00 P.M. PT (Businesswire)
13.12.17	Preliminary Data from Servier and Pfizer’s UCART19 Product Candidate Shows High Complete Remission Rate Across Two Phase I Adult and Pediatric Acute Lymphoblastic Leukemia Trials (Businesswire)
04.12.17	Cellectis Appoints Elsy Boglioli to Executive Vice President, Strategy and Corporate Development (Businesswire)
04.12.17	Cellectis Appoints Immuno-Oncology Leader Stéphane Depil to Position of Senior Vice President Research & Development and Chief Medical Officer (Businesswire)
04.12.17	Cellectis: Monthly Information on Share Capital and Company Voting Rights (Businesswire)
20.11.17	Cellectis Demonstrates Fine and Predictable Tuning of TALEN® Gene Editing Targeting to Improve T-cell Adoptive Immunotherapy (Businesswire)
13.11.17	Cellectis Reports Financial Results for Third Quarter and First Nine Months of 2017 (Businesswire)
08.11.17	Cellectis: Monthly Information on Share Capital and Company Voting Rights (Businesswire)
07.11.17	FDA Lifts Clinical Hold on Cellectis Phase 1 Clinical Trials with UCART123 in AML and BPDCN (Businesswire)
01.11.17	Cellectis Announces Two Oral Presentations and One Poster Presentation at the 2017 ASH Annual Meeting (Businesswire)
01.11.17	Servier and Pfizer Announce Preliminary Results of the First-in-Human Trials of UCART19 Will Be Presented at the 59th American Society of Hematology (ASH) Annual Meeting (Businesswire)
04.10.17	Mathieu Simon, M.D. Cellectis’ EVP & Chief Operating Officer, to Serve as Interim Chief Medical Officer (Businesswire)
04.10.17	Cellectis: Monthly Information on Share Capital and Company Voting Rights (Businesswire)
07.09.17	Cellectis: Monthly Information on Share Capital and Company Voting Rights (Businesswire)
05.09.17	Cellectis to Participate in Upcoming Investor Conferences (Businesswire)
05.09.17	Cellectis Reports Clinical Hold of UCART123 Studies (Businesswire)
17.08.17	Cellectis’ UCART123 Administered to First Patient with BPDCN in Phase I Clinical Trial at MD Anderson Cancer Center (Businesswire)
02.08.17	Cellectis Reports Financial Results for 2nd Quarter and First Six Months 2017 (Businesswire)
02.08.17	Cellectis: Monthly Information on Share Capital and Company Voting Rights (Businesswire)
25.07.17	Cellectis S.A.: Calyxt Announces Full Exercise of Over-Allotment Option and Closing of its Initial Public Offering (Businesswire)
24.07.17	Cellectis Granted Patent for CRISPR Use in T-Cells (Businesswire)
20.07.17	Cellectis S.A.: Calyxt Announces Pricing of $56.0 Million Initial Public Offering (Businesswire)
10.07.17	Cellectis: Calyxt Announces Proposed Initial Public Offering of $100.0 Million (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu CELLECTISAct. Nom.

Aktien Top/Flop

Meistgelesene Nachrichten